Key barriers to optimal manage­ment of adult asthma in Australia: physician and patient perspectives

References

• Masoli M, Fabian D, Holt S, et al.; Global Initiative for Asthma (GINA) Program. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy 2004;59:469–78
   Google Scholar
• Marks GB, Correll PK, Williamson M. Asthma in Australia 2005. Med J Aust 2005;183: 445–6
   Google Scholar
• Ampon RD, Williamson M, Correll PK, et al. Impact of asthma on self-reported health status and quality of life: a population based study of Australians aged 18–64. Thorax 2005;60:735–9
   PubMed Web of Science ®Google Scholar
• Rabe KF, Adachi M, Lai CK, et al. Worldwide severity and control of asthma in children and adults: the global asthma insights and reality surveys. J Allergy Clin Immunol 2004;114:40–7
   PubMed Web of Science ®Google Scholar
• Rabe KF, Vermeire PA, Soriano JB, et al. Clinical management of asthma in 1999: the Asthma Insights and Reality in Europe (AIRE) study. Eur Respir J 2000;16:802–7
   PubMed Web of Science ®Google Scholar
• Berger WE. Ciclesonide: a novel inhaled corticosteroid for the treatment of persistent asthma – a pharmacologic and clinical profile. Therapy 2005;2:167–178
   Google Scholar
• GINA pocket guide for asthma management and prevention. Updated 2005. Available from http://www.ginasthma.com [Last accessed 18 Sep 2006]
   Google Scholar
• Humbert M. The right tools at the right time. Chest 2006;130(Suppl):29S–40
   Google Scholar
• Larj MJ, Bleecker ER. Therapeutic responses in asthma and COPD. Corticosteroids. Chest 2004;126(Suppl):138S–49
   Google Scholar
• Pauwels RA, Pedersen S, Busse WW, et al. Early intervention with budesonide in mild persistent asthma: a randomised, double-blind trial. Lancet 2003;361:1071–6
   PubMed Web of Science ®Google Scholar
• Pearlman DS, Berger WE, Kerwin E, et al. Once-daily ciclesonide improves lung function and is well tolerated by patients with mild-to-moderate persistent asthma. J Allergy Clin Immunol 2005;116:1206–12
   PubMed Web of Science ®Google Scholar
• Langdon CG, Adler M, Mehra S, et al. Once-daily ciclesonide 80 or 320 microg for 12 weeks is safe and effective in patients with persistent asthma. Respir Med 2005;99:1275–85
   PubMed Web of Science ®Google Scholar
• Chapman KR, Patel P, D’Urzo AD, et al. Maintenance of asthma control by once-daily inhaled ciclesonide in adults with persistent asthma. Allergy 2005;60:330–7
   Google Scholar
• Suissa S, Ernst P, Benayoun S, et al. Low-dose inhaled corticosteroids and the prevention of death from asthma. N Engl J Med 2000;343:332–6
   PubMed Web of Science ®Google Scholar
• Rutherford C, Mills R, Gibson PG, et al. Improvement in health-related quality of life with fluticasone propionate compared with budesonide or beclomethasone dipropionate in adults with severe asthma. Respirology 2003;8:371–5
   PubMed Web of Science ®Google Scholar
• Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. National Institutes of Health, National Heart, Lung and Blood Institute 2002. Available from http://www.ginasthma.com [Last accessed 18 Sep 2006]
   Google Scholar
• Global Asthma Physician and Patient (GAPP) Survey: global adult highlights. Available from http://www.gappsurvey.org/pdf/global-overview.pdf [Last accessed 18 Sep 2006]
   Google Scholar
• Boulet LP. Perception of the role and potential side effects of inhaled corticosteroids among asthmatic patients. Chest 1998;113:587–92
   PubMed Web of Science ®Google Scholar
• Lipworth BJ. Systemic adverse effects of inhaled corticosteroid therapy: a systematic review and meta-analysis. Arch Intern Med 1999;159:941–55
   PubMed Web of Science ®Google Scholar
• Humbert M. Ciclesonide: a novel inhaled corticosteroid. Expert Opin Investig Drugs 2004;13:1349–60
   PubMed Web of Science ®Google Scholar
• Sawyer SM, Fardy HJ. Bridging the gap between doctors’ and patients’ expectations of asthma management. J Asthma 2003;40:131–8
   PubMed Web of Science ®Google Scholar
• Cochrane GM. Compliance and outcomes in patients with asthma. Drugs 1996;52(Suppl 6):12–9
   PubMed Web of Science ®Google Scholar
• Campbell LM. Once-daily inhaled corticosteroids in mild to moderate asthma: improving acceptance of treatment. Drugs 1999;58(Suppl 4):25–33
   PubMedGoogle Scholar
• Allen DB, Bielory L, Derendorf H, et al. Inhaled corticosteroids: past lessons and future issues. J Allergy Clin Immunol 2003;112(Suppl):S1–40
   Google Scholar
• Nathan RA, Nayak AS, Graft DF, et al. Mometasone furoate: efficacy and safety in moderate asthma compared with beclomethasone dipropionate. Ann Allergy Asthma Immunol 2001;86:203–10
   PubMed Web of Science ®Google Scholar
• Niphadkar P, Jagannath K, Joshi JM, et al. Comparison of the efficacy of ciclesonide 160 microg QD and budesonide 200 microg BID in adults with persistent asthma: a phase III, randomized, double-dummy, open-label study. Clin Ther 2005;27:1752–63
   PubMed Web of Science ®Google Scholar
• Lee DK, Fardon TC, Bates CE, et al. Airway and systemic effects of hydrofluoroalkane formulations of high-dose ciclesonide and fluticasone in moderate persistent asthma. Chest 2005;127:851–60
   PubMed Web of Science ®Google Scholar
• Chrousos GP, Ghaly L, Shedden A, et al. Effects of mometasone furoate dry powder inhaler and beclomethasone dipropionate hydrofluoroalkane and chlorofluorocarbon on the hypothalamic-pituitary-adrenal axis in asthmatic subjects. Chest 2005;128:70–7
   PubMed Web of Science ®Google Scholar
• Rohatagi S, Arya V, Zech K, et al. Population pharmacokinetics and pharmacodynamics of ciclesonide. J Clin Pharmacol 2003;43:365–78
   PubMed Web of Science ®Google Scholar
• Lipworth BJ, Kaliner MA, LaForce CF, et al. Effect of ciclesonide and fluticasone on hypothalamic-pituitary-adrenal axis function in adults with mild-to-moderate persistent asthma. Ann Allergy Asthma Immunol 2005;94:465–72
   PubMed Web of Science ®Google Scholar
• Kaliner MA. Pharmacologic characteristics and adrenal suppression with newer inhaled corticosteroids: a comparison of ciclesonide and fluticasone propionate. Clin Ther 2006;28:319–31
   PubMed Web of Science ®Google Scholar
• Derom E, Van De Velde V, Marissens S, et al. Effects of inhaled ciclesonide and fluticasone propionate on cortisol secretion and airway responsiveness to adenosine 5’monophosphate in asthmatic patients. Pulm Pharmacol Ther 2005;18:328–36
   PubMed Web of Science ®Google Scholar
• Fardon TC, Lee DK, Haggart K, et al. Adrenal suppression with dry powder formulations of fluticasone propionate and mometasone furoate. Am J Respir Crit Care Med 2004;170:960–6
   PubMed Web of Science ®Google Scholar
• Affrime MB, Kosoglou T, Thonoor CM, et al. Mometasone furoate has minimal effects on the hypothalamic-pituitary-adrenal axis when delivered at high doses. Chest 2000;118:1538–46
   PubMed Web of Science ®Google Scholar